Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.

AusPAR: Pembrolizumab (rch)

Australian Public Assessment Report

AusPAR

AusPAR Pembrolizumab (rch) [PDF, 3.56 MB]

AusPAR Pembrolizumab (rch) [Word, 6.42 MB]

Attachment: Product Information: Pembrolizumab (rch) [PDF, 230.46 KB]

Attachment: Product Information: Pembrolizumab (rch) [Word, 62.59 KB]

Attachment: Extract from Clinical Evaluation Report: Pembrolizumab (rch) [PDF, 2.91 MB]

Attachment: Extract from Clinical Evaluation Report: Pembrolizumab (rch) [Word, 5.49 MB]

Device/Product Name

Keytruda

Active ingredients

Pembrolizumab (rch)

AusPAR Date

14 October 2016

Published

18 October 2016

Submission Number

PM-2014-01928-1-4

Submission Type

New biological chemical entity

Decision

Approved